ABSTRACT
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases defined by ineffective hematopoiesis with dysplasia and an increased risk of acute myeloid leukemia (AML). 1 MDS is a heterogeneous entity with a variable clinical course; thus, accurate diagnosis and risk stratification are crucial to management of these patients. Although the World Health Organization (WHO) classification scheme provides information in relation to disease survival and risk of transformation to AML for the various subtypes of MDS (MDS with single-lineage dysplasia [ 
MDS-SLD], MDS with ring sideroblasts [MDS-RS], MDS with multilineage dysplasia [MDS-MLD], MDS with excess blasts [MDS-EB], and
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MDS with isolated del(5q)), little is known about the risk profile of MDS, unclassifiable (MDS-U). In these cases, neither the percentage of patients who transform to AML nor disease survival is known. In the 2008 classification, the WHO refined the category of MDS-U to describe patients who lack sufficient findings for classification into another "specific" MDS category. Three situations qualify for inclusion in this category. The first subcategory includes patients with refractory cytopenia with unilineage or multilineage dysplasia and 1% circulating blasts (MDS-U BL). The second subcategory includes patients with pancytopenia with unilineage dysplasia (MDS-U Pan). The third subcategory includes patients with persistent cytopenia(s), less than 5% bone marrow (BM) blasts, less than 1% peripheral blood (PB) blasts, less than 10% dysplastic cells in the BM, and presence of MDS-defining cytogenetic abnormalities (MDS-U CG). In one large series of patients with MDS, the overall incidence of MDS-U was 6%, but the relative proportion of the three subtypes is unknown. 2 To our knowledge, the three groups that comprise MDS-U have never been comprehensively investigated. One study reported an inferior prognosis in patients with MDS with features of MDS-SLD or MDS-MLD and with 1% circulating blasts, but the other MDS-U subtypes have not been specifically studied. 3 This study is designed to compare the clinicopathologic features and the molecular profiles of these three groups of MDS-U. We sought to determine if it is justified to place MDS-U with 1% circulating blasts, MDS-U with unilineage dysplasia plus pancytopenia, and MDS-U with MDS-defining cytogenetic abnormalities under the same category.
Materials and Methods
We searched the pathology archives at four large academic medical centers in the United States: Weill Cornell Medicine (WCMC/NYP), Massachusetts General Hospital, Stanford University Medical Center, and M.D. Anderson Cancer Center for newly diagnosed cases of MDS-U diagnosed between 2008 and 2015. All included cases had to meet one of the 2008 WHO classification requirements for MDS-U (described below). Clinical information, laboratory data, BM karyotype results, and treatment and follow-up information were retrieved from the electronic medical records. All patients with a history of malignancy, recent treatment with granulocyte colony-stimulating factor, or cytotoxic therapy exposure were excluded.
The International Prognostic Scoring SystemRevised (IPSS-R) score was calculated as previously described. 4 Disease progression was defined as when a patient met criteria for AML. This study was approved by the institutional review boards of all participating institutions. This study was conducted in accordance with the Declaration of Helsinki.
Pathology Review
Blood smears, BM aspirate smears, and core biopsy specimens were reviewed by at least one hematopathologist at each institution to confirm the diagnosis. PB blast counts were obtained by manual count of 200 cells. BM cellularity and the myeloid/erythroid ratio were estimated on the core biopsy specimen. For dyspoiesis, dysplastic changes had to be present in at least 10% of the cells in that lineage. A differential count based on 500 cells or all available cells was performed on the BM aspirate smears, and ring sideroblasts were assessed on Prussian bluestained BM aspirate smears. Patients with MDS-SLD, MDS-MLD, MDS-RS, and MDS with isolated del(5q) and 1% blasts in PB were classified as having MDS-U BL. Patients with sustained (ie, more than 6 months) pancytopenia with unilineage dysplasia were classified as having MDS-U Pan. Pancytopenia was defined as hemoglobin less than 10 g/dL, platelets less than 100 × 10 9 /L, and absolute neutrophil count (ANC) less than 1.8 × 10 9 /L. Cases with persistent (ie, more than 6 months) cytopenia(s), less than 5% blasts on BM aspirate smears, less than 1% blasts in the PB smear, less than 10% dysplastic cells in any myeloid lineage, and the presence of any MDS-defining cytogenetic abnormality as defined by the 2008 WHO classification were classified as having MDS-U CG.
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Cytogenetics
Conventional cytogenetic analysis was performed on G-banded metaphase cells prepared from unstimulated BM aspirate cultures using standard techniques. When possible, 20 metaphases were analyzed and the results reported using the International System for Human Cytogenetic Nomenclature. 6 
Mutation Studies
Myeloid mutational studies were performed as part of the routine clinical workup in eight cases at the original institution or at a commercial reference laboratory. Targeted next-generation sequencing using a panel designed for myeloid neoplasms was performed at WCMC/NYP on genomic DNA extracted from cytogenetics pellets from 10 additional cases. In these cases, genomic DNA was fragmented to 3 to 4 kb by shearing using a QSonica (Newtown, CT) Q800R2 instrument according to the manufacturer's recommendations. , and ZRSR2) recurrently mutated in myeloid malignancies was performed using the Thunderstorm system (Raindance Technologies, Billerica, MA) using a custom primer panel followed by sequencing using the Illumina (San Diego, CA) MiSeq (v3 chemistry) yielding 260-base pair (bp) paired end reads. Sequence adapters and low-quality reads were excluded or trimmed using Trimmomatic (Aachen, Germany) followed by mapping to the human reference genome (hs37d5) using BurrowsWheeler Aligner MEM, removing both discordant and nonuniquely mapping alignments. Variant calling was performed using the VarDict amplicon mode, excluding variants in low complexity and polymerase chain reaction primer regions. 7 Variants were subsequently annotated using SnpEff 4.1.
8 Common single-nucleotide polymorphisms likely to be nonsomatic with minor allele frequency greater than 0.25% were excluded from subsequent analysis with the exception of variants identified at least twice in the Catalog of Somatic Mutations in Cancer (COSMIC) v68.
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Statistical Analyses
For continuous variables, data are reported as median and range; statistical significance was determined by analysis of variance. For categorical and ordinal variables, data are reported as the number of patients if not specified. Statistical significance was assessed by Fisher's exact test or χ 2 test, as appropriate, for categorical variables and by the Kruskall-Wallis test for ordinal variables. Overall survival was calculated from the day of diagnosis to the date of death or last follow-up. Progression-free survival (PFS) was calculated from the time of diagnosis either to death or AML transformation. Distributions of overall survival (OS) and PFS were estimated by Kaplan-Meier curves. All P values are two-tailed and considered significant when less than .05. Statistical analysis was performed using R software for Windows.
Results
From an initial cohort of 41 cases, 14 had a history of exposure to cytotoxic therapies and were excluded.
A final cohort of 27 cases with de novo MDS-U was identified (six MDS-U BL, 13 MDS-U Pan, and eight MDS-U CG). All patients were adults, with a median age of 65 years (range, 29-86 years), evenly split between males and females (P > .05). The median follow-up period was 2.5 years (range, 5 months to 12 years). There was no significant association between age, sex, and presence of cytogenetic abnormalities with the MDS-U subtype (P > .05 for all comparisons). However, the mean IPSS-R score and the prevalence of cytogenetic abnormalities classified in the IPSS-R as "poor" or "very poor" were higher in the MDS-U BL subgroup compared with the other two groups (P = .04 and P = .02, respectively). The clinical and morphologic features of the cases in each subgroup are provided in ❚Table 1❚. Representative photomicrographs of the three subtypes of MDS-U are presented in ❚Image 1❚.
Among patients with MDS-U BL (n = 6), the most common cytopenia was anemia (n = 5), followed by thrombocytopenia (n = 4) and leukopenia (n = 4). Multilineage dysplasia was present in five of six cases while one case showed isolated dysmegakaryopoiesis. Cytogenetic abnormalities were present in all six cases, three of which were complex karyotypes.
All patients with MDS-U Pan had pancytopenia, in accordance with WHO criteria. Single-lineage dysplasia in the megakaryocytic lineage was identified in seven of 13; dyserythropoiesis was seen five of 13 and dysgranulopoiesis in one of 13. Cytogenetic abnormalities were present in five of 12 karyotyped cases, which were all unbalanced abnormalities (four deletions and one addition). One patient had a deletion of chromosome 5q, but the breakpoints did not overlap with those seen in MDS with isolated del(5q), and the morphology was not compatible with this MDS subgroup. One patient had a poorrisk cytogenetic abnormality, del(7q).
The MDS-U CG group most commonly had anemia (seven of eight patients), followed by thrombocytopenia (five of eight patients). Two patients presented with marked neutropenia (ANC <0.8 × 10 9 /L). All cases (by definition) had cytogenetic abnormalities, including one case with a complex karyotype, one with balanced translocations, and two with inversions, including one with the poor-risk cytogenetic abnormality inv(3)(q21q26.2) (n = 1).
Treatment modalities varied widely between institutions and between the three subgroups. Almost all patients with MDS-U BL received hypomethylating agents, either azacitadine or decitabine; one individual was treated with anti-PD-1 inhibitor. Patients in the MDS-U Pan subgroup received supportive care only (n = 9), azacitadine/ decitabine (n = 3), or cyclosporine (n = 1). In the MDS-U CG subgroup, most patients received supportive care only 
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AJCP / Original article (n = 4), but a subset was treated with allogeneic stem cell transplant (n = 3) or azacitadine (n = 1). At a median follow up of 2.5 years, five (18%) deaths from disease and four (14%) AML transformations were observed, all in the MDS-U BL subgroup. Evolution to other WHO-defined entities was observed in two (7%) individuals. In the MDS-U Pan group, one individual was diagnosed with chronic myelomonocytic leukemia-1 on bone marrow examination 2 years after the MDS-U diagnosis. In the MDS-U CG group, progression to MDS with excess blasts (MDS-EB) after 2.5 months was seen in one individual with 11q deletion. Patients with MDS-U BL had a median PFS and OS of 1.8 and 1.9 years, respectively, which was significantly shorter than that observed in the other two subgroups, for whom the median PFS and OS has not yet been reached (P < .001 for both PFS and OS; ❚Figure 1❚).
Myeloid mutational studies were performed on a subset of cases (n = 16; ❚Table 2❚). At least one oncogenic mutation was identified in 11 (69%) of 16 cases. In the MDS-U BL subgroup, three of three cases had at least one mutation. The MDS-U Pan group had the lowest rate of mutations, with only three of seven cases harboring at least one mutation. In the MDS-U CG group, five of six cases had at least one mutation. These differences in mutation incidence were not statistically significant. No subtype-specific mutation patterns were identified, with alterations in TP53, EZH2, ASXL2, TET2, CALR, SETBP1, and SF3B1 present across subtypes.
Discussion
Cases of MDS classified as MDS-U are quite rare and possibly underrecognized. To our knowledge, this multi-institutional study provides the largest comparative analysis of the three subtypes of MDS-U recognized by the WHO classification. Our results demonstrate a striking difference in clinical outcomes among MDS-U subgroups. We confirm that cases of MDS-U BL have a high rate of progression to AML and a shorter median OS and PFS than MDS-U Pan and CG, the two latter categories representing relatively indolent diseases. Our findings suggest that the presence of PB blasts in MDS, even at a level as low as 1%, signifies an aggressive disease more akin to MDS with excess blasts (MDS-EB) than to lower grade MDS subtypes (MDS-SLD, MDS-MLD, and MDS-RS). The median survival of our patients with MDS-U BL was only 1.8 years, comparable to that reported for patients with MDS-EB with 5% to 10% BM blasts or at least 2% circulating blasts. 4 An additional feature that may contribute to the more aggressive behavior of MDS U-BL compared with other MDS-U subtypes is multilineage dysplasia, which was seen in most of the MDS-U BL cases but by definition is absent from MDS-U Pan and MDS-U CG. The category of MDS-U was initially included in the third edition of the WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues as a "wastebasket" to collect cases of MDS not otherwise classifiable, but it was refined in the fourth edition to account specifically for the three defined situations. The finding in one study that 1% circulating blasts in patients with low-grade MDS portended a poor prognosis supported the creation of MDS-U BL. 3 In 2007, Verburgh et al 10 described a small group of patients with pancytopenia and unilineage dysplasia as difficult to classify by WHO criteria, representing the MDS-U Pan group. Finally, the observation that clonal cytogenetic abnormalities seen in MDS without morphologic evidence of dysplasia often precedes a diagnosis of MDS led to the proposal of the MDS-U CG subgroup.
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The only prior study of clinical outcome in 124 patients with MDS-U did not include MDS-U CG due to low numbers. This study found no difference in mortality between MDS-U BL and Pan, with a median overall survival of 35 and 30 months, respectively. On the basis of these findings, the authors suggested consolidation of MDS-U with MDS-MLD. 2 In contrast, we found that MDS-U Pan had an indolent course overall. This difference may be attributable to different demographics or treatment approaches between the two studies, as the prior study did not report age or treatment in their cohort. Compared with MDS-U Pan, the MDS-U BL group in our study had higher IPSS-R scores and more frequent karyotypic abnormalities. Recent advances in molecular biology particularly following the introduction of next-generation sequencing methodology have allowed assessment of mutations as part of the routine diagnostic workup of patients with MDS. At least one somatic mutation can be identified in 78% to 90% of patients with MDS, providing an putative marker of clonality in individuals with a normal karyotype. 12, 13 The rate of somatic mutation observed in our MDS-U cases was 71% overall, similar to studies of large MDS cohorts. 13 There were no statistically significant differences in the rate of mutations among the three MDS-U subgroups in our study, although this may be possibly due to the relatively small sample size. Nearly all cases of MDS-U BL and CG had somatic mutations, while only three of seven MDS-U Pan cases had mutations. Several studies have suggested that mutations in TP53, ASXL1, and EZH2 in MDS are associated with a poor outcome.
14,15 However, we found alterations in these three "high-risk" genes across all MDS-U subtypes, including several cases that exhibited indolent behavior requiring no treatment. Our findings are similar to those recently reported in a large retrospective sequencing study of individuals with clonal cytopenia of undetermined significance, who showed a mutation rate in "high-risk" genes that was comparable to individuals with MDS. 16 Thus, the role of mutational analysis as a prognostic tool in MDS-U appears presently unclear.
To our knowledge, the current study is the first to show the presence of point mutations in exon 9 of calreticulin (CALR) in MDS-U. Somatic CALR mutations are found in 70% to 84% of patients with essential thrombocythemia or primary myelofibrosis with wild-type JAK2 and MPL and occasionally in other myeloid neoplasms. 17 Two cases in this series (cases 10 and 26, one MDS-U Pan and one MDS-U CG) had missense CALR mutations in exon 9 that were located between c.1114 and c.1174 of the CALR gene, a region previously identified as an area of genomic instability where point mutation may precede the development of type 1 mutations (p.L367fs*46). 18 None of the CALR-mutated patients had thrombocytosis or other features associated with myeloproliferative neoplasms. CALR mutations have been infrequently observed in MDS. 17, [19] [20] [21] Prior large cohort studies have found the rate of CALR mutation in MDS to be 0% to 8%. 17, 19, 22 The significance of these findings is unclear in this limited study; future research may shed more light on the role of point mutations in CALR in the pathophysiology of MDS.
Although this represents the largest series studying the WHO entity of MDS-U, the implications of this study for the classification of MDS may be limited by the relatively small number of patients. In addition, retrospective identification of these cases can be difficult given hematopathologists' reluctance to diagnose MDS in patients with isolated cytogenetic changes in the absence of sufficient morphologic dysplasia. Thus, it is possible that our sample did not include all MDS-U cases at participating institutions. However, at present, we are unable to recommend that all cases of MDS-U be consolidated within the category of MDS-MLD as suggested by others 18 in light of the distinctly poorer outcomes of the MDS-U BL subgroup.
Our findings demonstrate the importance of accurate assessment of circulating blasts in PB, even at low counts, for prognostication and classification of patients with MDS. Although the reliability of a 1% blast count may be limited as a single observation, a cutoff of 1% circulating blasts has been shown to have a clear prognostic value in various myeloid neoplasms. 2, 3, [23] [24] [25] [26] Further studies showing persistence of 1% blasts on separate occasions or using more sensitive modalities for quantification may help elucidate the prognostic significance of circulating blasts in MDS.
In conclusion, MDS with 1% circulating blasts represents a distinct subgroup of MDS-U with a poor prognosis. The high rate of progression to AML and the relatively short median overall survival time of MDS-U BL suggest that this MDS-U subtype could be appropriately classified together within MDS-EB, in effect lowering the threshold of "excess blasts" in the PB from 2% to 1%. Conversely, it is important to ensure the accuracy of identifying 1% circulating blasts in patients with MDS, and accordingly, the revised fourth edition of the WHO classification now requires that this finding be demonstrated in two PB smear examinations. 27 In contrast, cytogenetic changes in the absence of myelodysplasia and pancytopenia with unilineage dysplasia may represent more indolent forms of MDS. Therefore, careful evaluation of PB smears for circulating blasts remains an essential tool in identifying patients with myelodysplasia to appropriately categorize the relatively aggressive MDS-U subgroup defined by 1% peripheral blasts. 
